Search Results - "Pulmonary pharmacology & therapeutics"

Refine Results
  1. 1

    Lung cancer in patients with idiopathic pulmonary fibrosis by Karampitsakos, Theodoros, Tzilas, Vasilios, Tringidou, Rodoula, Steiropoulos, Paschalis, Aidinis, Vasilis, Papiris, Spyros A, Bouros, Demosthenes, Tzouvelekis, Argyris

    Published in Pulmonary pharmacology & therapeutics (01-08-2017)
    “…Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease of unknown etiology. With a gradually increasing worldwide prevalence and a…”
    Get full text
    Journal Article
  2. 2

    Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients by Hogan II, Reed B., Hogan III, Reed B., Cannon, Tim, Rappai, Maria, Studdard, John, Paul, Doug, Dooley, Thomas P.

    Published in Pulmonary pharmacology & therapeutics (01-08-2020)
    “…The COVID-19 pandemic due to SARS-CoV-2 infection can produce Acute Respiratory Distress Syndrome as a result of a pulmonary cytokine storm. Antihistamines are…”
    Get full text
    Journal Article
  3. 3

    The immunomodulatory effects of macrolide antibiotics in respiratory disease by Pollock, Jennifer, Chalmers, James D.

    Published in Pulmonary pharmacology & therapeutics (01-12-2021)
    “…Macrolide antibiotics are well known for their antibacterial properties, but extensive research in the context of inflammatory lung disease has revealed that…”
    Get full text
    Journal Article
  4. 4

    Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects by Al-kuraishy, Hayder M., Al-Gareeb, Ali I., Qusty, Naeem, Cruz-Martins, Natália, El-Saber Batiha, Gaber

    Published in Pulmonary pharmacology & therapeutics (01-04-2021)
    “…Coronavirus virus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), actually…”
    Get full text
    Journal Article
  5. 5

    Myricetin inhibits TNF-α-induced inflammation in A549 cells via the SIRT1/NF-κB pathway by Chen, Min, Chen, Ziyu, Huang, Dan, Sun, Chaoqun, Xie, Jinye, Chen, Tingting, Zhao, Xuanna, Huang, Yujie, Li, Dongming, Wu, Bin, Wu, Dong

    Published in Pulmonary pharmacology & therapeutics (01-12-2020)
    “…Although myricetin exerts anti-inflammation, anti-cancer, and anti-oxidation effects, the relationship between myricetin and tumor necrosis factor alpha…”
    Get full text
    Journal Article
  6. 6

    Use of animal models in IPF research by Carrington, R., Jordan, S., Pitchford, S.C., Page, C.P.

    Published in Pulmonary pharmacology & therapeutics (01-08-2018)
    “…Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with a poor prognosis and limited treatment options. Many compounds have shown…”
    Get full text
    Journal Article
  7. 7

    BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration by Garceau, Denis, Chauret, Nathalie

    Published in Pulmonary pharmacology & therapeutics (01-06-2019)
    “…BLU-5937 is a small molecule that was shown to be a potent, selective and non-competitive P2X3 homotrimeric receptor antagonist. P2X3 receptors are ATP…”
    Get full text
    Journal Article
  8. 8

    Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils by Brusselle, Guy, Germinaro, Matthew, Weiss, Sivan, Zangrilli, James

    Published in Pulmonary pharmacology & therapeutics (01-04-2017)
    “…Abstract Introduction Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Pirfenidone, nintedanib and N -acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis by Rogliani, Paola, Calzetta, Luigino, Cavalli, Francesco, Matera, Maria Gabriella, Cazzola, Mario

    Published in Pulmonary pharmacology & therapeutics (01-10-2016)
    “…Abstract Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year. Pirfenidone and nintedanib were approved for treatment of…”
    Get full text
    Journal Article
  11. 11

    Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view by Saturni, S, Bellini, F, Braido, F, Paggiaro, P, Sanduzzi, A, Scichilone, N, Santus, P.A, Morandi, L, Papi, A

    Published in Pulmonary pharmacology & therapeutics (01-04-2014)
    “…Abstract Randomized Controlled Trials (RCTs) are the “gold standard” for evaluating treatment outcomes providing information on treatments “efficacy”. They are…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach by Nogueira-Ferreira, Rita, Vitorino, Rui, Ferreira, Rita, Henriques-Coelho, Tiago

    Published in Pulmonary pharmacology & therapeutics (01-12-2015)
    “…Abstract Pulmonary arterial hypertension (PAH) is responsible for the premature death mainly because of progressive and severe heart failure. This disease is…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Cough and airway disease: The role of ion channels by Bonvini, Sara J., Belvisi, Maria G.

    Published in Pulmonary pharmacology & therapeutics (01-12-2017)
    “…Cough is the most common reason for patients to visit a primary care physician, yet it remains an unmet medical need. It can be idiopathic in nature but can…”
    Get full text
    Journal Article
  17. 17

    The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination by Robaina Cabrera, Carmen Lorena, Keir-Rudman, Sandra, Horniman, Nick, Clarkson, Nick, Page, Clive

    Published in Pulmonary pharmacology & therapeutics (01-08-2021)
    “…Studies with Cannabis Sativa plant extracts and endogenous agonists of cannabinoid receptors have demonstrated anti-inflammatory, bronchodilator, and…”
    Get full text
    Journal Article
  18. 18

    Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation by Wang, Di, Chai, Xiao-qing, Magnussen, Costan G., Zosky, Graeme R., Shu, Shu-hua, Wei, Xin, Hu, Shan-shan

    Published in Pulmonary pharmacology & therapeutics (01-10-2019)
    “…While effective treatments for acute respiratory distress syndrome (ARDS) are lacking, mechanical lung ventilation can sustain adequate gas exchange in…”
    Get full text
    Journal Article
  19. 19

    The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma by Erpenbeck, Veit J, Popov, Todor A, Miller, David, Weinstein, Steven F, Spector, Sheldon, Magnusson, Baldur, Osuntokun, Wande, Goldsmith, Paul, Weiss, Markus, Beier, Jutta

    Published in Pulmonary pharmacology & therapeutics (01-08-2016)
    “…Abstract Background There is an unmet medical need for allergic asthma patients who are uncontrolled on conventional therapies. The aim of this study was to…”
    Get full text
    Journal Article
  20. 20

    Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 by Maslennikov, Roman, Ivashkin, Vladimir, Vasilieva, Ekaterina, Chipurik, Maxim, Semikova, Polina, Semenets, Victoria, Russkova, Tatyana, Levshina, Anna, Grigoriadis, Diana, Magomedov, Shamil, Efremova, Irina, Dzhakhaya, Natiya

    Published in Pulmonary pharmacology & therapeutics (01-08-2021)
    “…Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of…”
    Get full text
    Journal Article